<DOC>
	<DOCNO>NCT01828008</DOCNO>
	<brief_summary>To study safety efficacy CD20 antibody usage follow CIK transfusion refractory and/or chemoresistant lymphoma .</brief_summary>
	<brief_title>Treatment CD20 Antibody Plus CIK Patients With Refractory Lymphomas</brief_title>
	<detailed_description>Autologous CIK transfusion within 3 day post CD20 antibody treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>diagnose Bcell lymphoma CD20 positiveness , need therapy refuse therapy need tolerate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Mabthera</keyword>
	<keyword>cytokine induce killer cell</keyword>
</DOC>